Highlights

  • EBOS Group (ASX:EBO) shares traded at AUD 17.66, down 0.11% at the time of writing on 28 August 2026.
  • The company reported FY26 Revenue of AUD 13.5 billion, up 9.9%, while underlying EBITDA increased 5.0% to AUD 614 million.
  • Healthcare revenue increased 8.5% to AUD 12.6 billion, supported by pharmacy, hospital medicines, medical technology and contract logistics.
  • EBOS completed its four-year AUD 360 million distribution centre renewal program and expects lower Capital intensity in FY27.

EBOS Group Limited (ASX:EBO) remained in focus within the healthcare sector, with shares trading at AUD 17.66, down 0.11% at the time of writing on 28 August 2026. Investors continue to assess the company following its FY26 results, which showed revenue and EBITDA growth across a diversified portfolio spanning pharmaceutical distribution, community pharmacy, medical technology and animal care.

The broader Australian market was trading higher, with the S&P/ASX 200 (ASX:XJO) at 9,074.40 points, up 0.40% (+36.20) today. The S&P/ASX 300 (ASX:XKO) was trading at 9,006.20 points, up 0.39% (+34.80). By comparison, the S&P/ASX 200 Health Care (ASX:XHJ) was trading at 31,753.60 points, down 0.12% (-38.80).

Short-term share price movements can reflect market sentiment, investor positioning and sector conditions. However, a single session does not necessarily indicate a change in the underlying fundamentals of the business.

FY26 Results

EBOS released its FY26 results on 19 August 2026, reporting revenue growth of 9.9% to AUD 13.487 billion. Underlying EBITDA increased 5.0% to AUD 614 million, while gross Operating Revenue rose 6.5% to AUD 1.743 billion.

Underlying NPAT was AUD 250 million, down 3.1%, with the company pointing to higher Depreciation and Amortisation expenses and financing costs associated with its recent Investment cycle. Statutory NPAT, meanwhile, increased 4.7% to AUD 225 million.

The company maintained its final Dividend at NZ 61.5 cents per share. Leverage ended FY26 at 2.1 times, remaining inside EBOS’ target range of 1.7 to 2.3 times.

An important feature of the FY26 result was the completion of EBOS’ four-year AUD 360 million distribution centre renewal program. All major facilities are now operational, shifting the focus from construction and investment towards utilisation, productivity and cash generation.

Healthcare Growth

Healthcare remains the core Earnings engine of EBOS Group. The segment generated FY26 revenue of AUD 12.580 billion, up 8.5%, while underlying EBITDA increased 3.2% to AUD 516 million.

Growth came from Community Pharmacy, Hospital Medicines, Medical Technology and Contract Logistics. The company highlighted continued Demand for GLP-1 and other high-value medicines, expansion of its network and contributions from acquisitions.

Within Community Pharmacy, revenue increased 10.2% to AUD 7.1 billion. Demand for higher-value medicines remained supportive, while EBOS maintained its PBS Market Share despite competitive conditions. The company is also targeting productivity improvements at its Kemps Creek distribution centre, with a 30% uplift versus the previous site targeted by the end of FY27.

Hospital medicines, consumables and other healthcare revenue increased 4.3% to AUD 3.8 billion, supported by a record hospital sales result and growth across aged-care and healthcare customers. Contract Logistics gross operating revenue rose 13.1% to AUD 174 million, while the new Perth Facility added capacity to the company’s national healthcare logistics footprint.

Pharmacy Network

EBOS’ Retail Pharmacy Brands Business also delivered continued expansion during FY26.

TerryWhite Chemmart network sales increased to approximately AUD 2.9 billion, up 9.2%, while like-for-like network sales increased 7.6%. Like-for-like dispensary sales rose 8.5%.

The broader pharmacy network reached 780 stores, an increase of 86 from the prior year, reflecting the addition of MediAdvice and other banner growth. CareClinic delivered more than 1.2 million health service interactions during FY26, highlighting EBOS’ increasing exposure to healthcare services delivered through community pharmacies.

Owned brands also remained an important growth area, with network sales increasing 11% during the year. EBOS continues investing in digital engagement, loyalty and retail media alongside pharmacy education and health services.

These initiatives broaden the company’s earnings exposure beyond traditional pharmaceutical wholesaling and could increase the role of pharmacy-based services within its overall healthcare platform.

Medical Technology

Medical Technology represents another growth avenue for EBOS. FY26 revenue increased 5.5%, or 8.4% on a constant currency basis, supported by organic growth and acquisitions.

Growth across Australia and New Zealand included neurosurgery, neurovascular intervention and urology, while the Southeast Asia and Hong Kong operations expanded across spine, orthopaedics, cardiology and ophthalmology.

Biologics also continued building momentum. Sales of the Allovance acellular dermal matrix portfolio increased by more than 15% during FY26. EBOS completed four strategic acquisitions that expanded its exposure across oncology, orthopaedics, aesthetics and plastic and reconstructive surgery.

For investors, this part of the business provides exposure to higher-value medical technologies and specialised procedures, complementing the scale-driven Economics of pharmaceutical distribution.

Investor Focus

EBOS enters FY27 with its major infrastructure investment cycle largely complete. Management expects Capital Expenditure to decline materially to approximately AUD 100 million in FY27, which is expected to support stronger free Cash Flow generation.

The company is targeting FY27 underlying EBITDA of AUD 635 million to AUD 655 million. Growth is expected to come from higher distribution network utilisation, pharmacy earnings expansion, Medical Technology growth and new products and customers in Animal Care.

Investors are therefore likely to focus on whether the newly completed distribution Assets translate into productivity benefits and better returns on invested capital. Pharmacy competition, medicine mix, healthcare funding arrangements, Acquisition integration and cost pressures are also likely to remain key areas of attention.

The company’s scale provides meaningful exposure to structural healthcare demand, but execution remains important as EBOS moves from a period of heavy Capital Investment into one focused more heavily on optimisation and cash generation.

Final Takeaway

EBOS Group (ASX:EBO) shares traded at AUD 17.66, down 0.11% at the time of writing on 28 August 2026. The modest daily movement comes while investors assess a FY26 result that included AUD 13.5 billion of revenue, AUD 614 million of underlying EBITDA and continued expansion across healthcare and pharmacy operations.

The completion of the AUD 360 million distribution centre renewal program represents an important transition point for the company. With major infrastructure spending largely behind it, attention is shifting towards productivity, free cash flow, healthcare network growth and returns from recent investments.

A daily share price movement alone does not necessarily reflect a change in EBOS Group’s underlying fundamentals. Longer-term assessment is likely to centre on earnings growth, healthcare demand, operational execution and the company’s ability to generate stronger returns from its expanded platform.